ALXO (ALX Oncology Holdings) FCF Margin %: 0.00% (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ALXO ALX Oncology Holdings Inc ALXO
31 GF Score
Price $2.00
! 3 Warning Signs
View Full Analysis

What is ALX Oncology Holdings FCF Margin %?

ALX Oncology Holdings ALXO +1.01% 31 FCF Margin % is 0.00% as of Jun. 2026. GuruFocus rates ALXO with a GF Score™ of 31/100. The stock has 3 warning signs investors should review. Among 956 Biotechnology companies, ALX Oncology Holdings ranks worse than 104602.41% on this metric.

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. ALX Oncology Holdings's Free Cash Flow for the three months ended in Jun. 2026 was $-16.07 Mil. ALX Oncology Holdings's Revenue for the three months ended in Jun. 2026 was $0.00 Mil. Therefore, ALX Oncology Holdings's FCF Margin % for the quarter that ended in Jun. 2026 was 0.00%.

As of today, ALX Oncology Holdings's current FCF Yield % is -25.65%.

The historical rank and industry rank for ALX Oncology Holdings's FCF Margin % or its related term are showing as below:


During the past 8 years, the highest FCF Margin % of ALX Oncology Holdings was -304.46%. The lowest was -3241.96%. And the median was -669.71%.

ALXO's FCF Margin % is not ranked *
in the Biotechnology industry.
Industry Median: -80.565
* Ranked among companies with meaningful FCF Margin % only.

ALX Oncology Holdings FCF Margin % Related Terms

ALX Oncology Holdings FCF Margin % Historical Data

* Premium members only.

The historical data trend for ALX Oncology Holdings's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

ALX Oncology Holdings FCF Margin % Chart

ALX Oncology Holdings Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
FCF Margin %
Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00

ALX Oncology Holdings Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
FCF Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

ALXO vs CYDY, BCYC, ELDN: FCF Margin % Comparison

For the Biotechnology subindustry, ALX Oncology Holdings's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

ALX Oncology Holdings FCF Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, ALX Oncology Holdings's FCF Margin % distribution charts can be found below:

* The bar in red indicates where ALX Oncology Holdings's FCF Margin % falls into.


ALXO
31GF Score
ALX Oncology Holdings Inc ALXO
FCF Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

ALX Oncology Holdings FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

ALX Oncology Holdings's FCF Margin for the fiscal year that ended in Dec. 2025 is calculated as

FCF Margin=Free Cash Flow (A: Dec. 2025 )/Revenue (A: Dec. 2025 )
=-84.354/0
= %

ALX Oncology Holdings's FCF Margin for the quarter that ended in Jun. 2026 is calculated as

FCF Margin=Free Cash Flow (Q: Jun. 2026 )/Revenue (Q: Jun. 2026 )
=-16.074/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about FCF Margin % →
What does a FCF Margin % of 0.00% mean?
ALX Oncology Holdings (ALXO) has a FCF Margin % of 0.00% as of Jun. 2026. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on ALX Oncology Holdings and its competitors. According to the industry distribution chart, ALX Oncology Holdings ranks #999999 out of 956 companies in the Biotechnology industry.
Is ALX Oncology Holdings' FCF Margin % too high?
ALX Oncology Holdings' current FCF Margin % is 0.00%. Based on the distribution chart, ALX Oncology Holdings ranks #999999 out of 956 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, ALX Oncology Holdings has a GF Score™ of 31/100, reflecting its overall financial health beyond just this single metric.
How does ALX Oncology Holdings' FCF Margin % compare to CYDY and BCYC?
According to the Biotechnology industry distribution chart, ALX Oncology Holdings ranks #999999 out of 956 companies for FCF Margin %. This places ALX Oncology Holdings in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Biotechnology company?
A good FCF Margin % depends on the Biotechnology industry context. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on ALX Oncology Holdings and its competitors. ALX Oncology Holdings's current FCF Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ALX Oncology Holdings stock overvalued right now?
ALX Oncology Holdings (ALXO) has a current FCF Margin % of 0.00%. The current FCF Margin % is 0.00%. ALX Oncology Holdings' overall GF Score™ is 31/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For ALX Oncology Holdings (ALXO), the current FCF Margin % is 0.00% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

ALX Oncology Holdings Business Description

Address 323 Allerton Avenue, South San Francisco, CA, USA, 94080
ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. It is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.
31GF Score

Get the complete analysis for ALXO

FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.00
Price